Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04044859
Title ADP-A2M4CD8 as Monotherapy or in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Adaptimmune

esophageal cancer

gastroesophageal junction adenocarcinoma

transitional cell carcinoma

head and neck cancer

ovarian cancer

stomach cancer


endometrial cancer

lung non-small cell carcinoma


ADP-A2M4 cells

Age Groups: adult | senior
Covered Countries USA | ESP | CAN | BEL

No variant requirements are available.